We are thrilled to convey our heartfelt congratulations to Imbria Pharmaceuticals on the outstanding results from the Phase 2 IMPROVE-HCM clinical trial. The trial, which evaluated ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), has shown significant improvements in patient-reported symptoms and exercise performance, marking a promising advancement in the treatment of this challenging condition.
As a specialized Contract Research Organization (CRO), we are proud to have been able to contribute to some extent. Our team recruited and supported the site in Oxford University’s Radcliffe Department of Medicine, which played a crucial role in this pivotal clinical trial. The site demonstrated exceptional performance, ensuring high-quality data collection and patient care, which were instrumental in achieving these positive outcomes.
The trial’s results were presented during a late-breaking clinical trial session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24) and published in the “Journal of the American College of Cardiology (JACC)”. These findings highlight the potential of ninerafaxstat to address the unmet needs of nHCM patients by improving their symptoms and functional capacity, which makes a difference for their quality of life.
Imbria Pharmaceuticals’ dedication to advancing treatments for cardiometabolic disorders is commendable, and we are honored to have played a role in this significant milestone and will continue to work for Imbria in their mission to improve patient outcomes.
For more information on the trial and its findings, please refer to the publication in JACC.
Once again, congratulations to the entire team at Imbria Pharmaceuticals. We are excited about the future developments and the positive impact these advancements will have on patients’ lives.
